6 research outputs found
Proliferation-associated miRNAs-494, -205, -21 and -126 detected by in situ hybridization: expression and prognostic potential in breast carcinoma patients
PurposeTo
visualize by in situ hybridization (ISH) the levels of a set of
proliferation-associated miRNAs and to evaluate their impact and
clinical applicability in prognostication of invasive breast carcinoma.MethodsTissue
specimen from breast carcinoma patients were investigated for
miRNAs-494, -205, -21 and -126. Prognostic associations for levels of
miRNAs were analyzed based on complete clinical data and up to 22.5-year
follow-up of the patient material (n = 285). For detection of the miRNAs, an automated sensitive protocol applying in situ hybridization was developed.ResultsMiRNA-494
indicated prognostic value for patients with invasive breast carcinoma.
Among node-negative disease reduced level of miRNA-494 predicted
8.5-fold risk of breast cancer death (p = 0.04).
Altered levels and expression patterns of the studied miRNAs were
observed in breast carcinomas as compared to benign breast tissue.ConclusionsThe
present paper reports for the first time on the prognostic value of
miRNA-494 in invasive breast cancer. Particularly, detection of
miRNA-494 could benefit patients with node-negative breast cancer in
identifying subgroups with aggressive disease. Based on our experience,
the developed automatic ISH method to visualize altered levels of
miRNAs-494, -205, -21 and -126 could be applied to routine pathology
diagnostics providing that conditions of tissue treatment, especially
fixation delays, are managed.</div
Remdesiviiri sairaalahoitoisessa COVID-19-taudissa : pragmaattinen, adaptiivinen, satunnaistettu Solidarity Finland -monikeskustutkimus
Lähtökohdat : Remdesiviiriä tutkittiin Solidarity Finland -tutkimuksessa. Menetelmät : COVID-19-taudin takia sairaalahoitoon joutuneet potilaat satunnaistettiin saamaan standardihoitoa tai sen lisäksi remdesiviiriä. Solidarity-tutkimuksessa ja satunnaistettujen tutkimusten meta-analyysissä ensisijainen päätetapahtuma oli sairaalahoitoajan kuolleisuus. Tulokset : Rekrytoimme 208 potilasta yhdestätoista sairaalasta. Sairaalahoidon aikana remdesiviiriryhmässä (n = 114) kuoli 1 % ja standardihoitoryhmässä (n = 94) 4 %. Invasiiviseen hengityslaitehoitoon joutui 5 % molemmissa ryhmissä. Tehohoitoa sai 11 % remdesiviiri- ja 12 % standardihoitoryhmässä. Maksaentsyymit nousivat merkittävästi 5 %:lla remdesiviiri- ja 2 %:lla standardihoitoryhmässä. Meta-analyysin alaryhmäanalyysissä remdesiviiri vähensi kuoleman riskiä potilailla, jotka eivät sairaalahoidon alkaessa saaneet hengityslaitehoitoa (RR 0,85, 95 % LV 0,75–0,96). Päätelmät : Suomessa on pandemian aikana mahdollista rekrytoida merkittävä määrä potilaita suuriin, satunnaistettuihin tutkimuksiin, joilla voidaan saada luotettavia tuloksia nopeasti. Remdesiviiristä voi olla apua sairaalahoitoisessa COVID-19-taudissa varhain aloitettuna.publishedVersionPeer reviewe
Effect of remdesivir post hospitalization for COVID-19 infection from the randomized SOLIDARITY Finland trial
We report the first long-term follow-up of a randomized trial (NCT04978259) addressing the effects of remdesivir on recovery (primary outcome) and other patient-important outcomes one year after hospitalization resulting from COVID-19. Of the 208 patients recruited from 11 Finnish hospitals, 198 survived, of whom 181 (92%) completed follow-up. At one year, self-reported recovery occurred in 85% in remdesivir and 86% in standard of care (SoC) (RR 0.94, 95% CI 0.47-1.90). We infer no convincing difference between remdesivir and SoC in quality of life or symptom outcomes (p > 0.05). Of the 21 potential long-COVID symptoms, patients reported moderate/major bother from fatigue (26%), joint pain (22%), and problems with memory (19%) and attention/concentration (18%). In conclusion, after a one-year follow-up of hospitalized patients, one in six reported they had not recovered well from COVID-19. Our results provide no convincing evidence of remdesivir benefit, but wide confidence intervals included possible benefit and harm.Peer reviewe
PTTG1-interacting protein (PTTG1IP/PBF) predicts breast cancer survival
Background: PTTG1-interacting protein (PTTG1IP) is an oncogenic protein, which participates in metaphase-anaphase
transition of the cell cycle through activation of securin (PTTG1). PTTG1IP promotes the shift of securin from the cell
cytoplasm to the nucleus, allowing the interaction between separase and securin. PTTG1IP overexpression has been
previously observed in malignant disease, e.g. in breast carcinoma. However, the prognostic value of PTTG1IP in breast
carcinoma patients has not previously been revealed.
Methods: A total of 497 breast carcinoma patients with up to 22-year follow-up were analysed for PTTG1IP and securin
immunoexpression. The results were evaluated for correlations with the clinical prognosticators and patient survival.
Results: In our material, negative PTTG1IP immunoexpression predicted a 1.5-fold risk of breast cancer death (p = 0.02).
However, adding securin immunoexpression to the analysis indicated an even stronger and independent prognostic
power in the patient material (HR = 2.5, p < 0.0001). The subcellular location of securin was found with
potential prognostic value also among the triple-negative breast carcinomas (n = 96, p = 0.052).
Conclusions: PTTG1IP-negativity alone and in combination with high securin immunoexpression indicates a high risk
of breast cancer death, resulting in up to 14-year survival difference in our material.peerReviewe